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INTRODUCTION
Background 
Japanese encephalitis is the leading viral cause of Acute Encephalitis Syndrome 
(AES) in Asia.  The disease primarily affects children under the age of fifteen. 70% of 
those who  develop illness either die or survive with a long term neurological disability.  
Since the first Case of JE was documented in the late 19th century; the disease has spread 
beyond its early domain- traveling as far as Australia by 2000.Over the past 60 years it is 
estimated  that  JE  has  infected~  10  million  children  globally,  killing  3  million  and 
causing long-term disability in 4 million.
Current Scenario in India
JE virus transmission has been widespread in India. The first evidence of presence 
of JE virus dates back to 1952 in Nagpur subdivision of Maharashtra. JE was clinically 
diagnosed for the first time in 1955 at Vellore, North Arcot district of Tamil Nadu. In 
subsequent  years,  outbreaks    have  occurred in  various  states  and Union Territories 
( UTs) in the country. The first  major JE epidemic was reported from Burdwan and 
Bankura  districts  of  West  Bengal  in  1973  followed  by  another  outbreak  in  1976. 
Outbreaks  have  been reported  from States  like  Uttar  Pradesh,  West  Bengal,  Assam, 
Andhra Pradesh, Karnataka, Bihar, Tamil Nadu, Haryana and other states through the 
years.
The Directorate of National Vector Borne Disease control Programme (NVBDCP) 
formerly known as the National Anti Malaria Programme (NAMP) has been monitoring 
JE incidence in the country since 1978. Though cases of JE have been reported from 26 
states and UT’s occasionally in some years since 1978, repeated outbreaks have been 
reported only from 12 States.
          The table below highlights the case load in some of the states during last 5 years 
(2001-  2005).   However,  the  disease  reporting  has  been  passive  without  adequate 
diagnostic  support.   These  are  reported  cases  through  passive  surveillance  without 
adequate diagnostics support.
 The Case Fatality Rate (CFR) due to JE in India has been around 24 % with wide 
variations in states. Annual reported cases due to JE ranges between 1037 and 6550 
while deaths due to JE range between292 and 1645.
THE EPIDEMIOLOGY OF JAPANESE ENCEPHALITIS
The JE Virus
JE virus (JEV) is a member of the genus Flaviviridae, together with Yellow Fever 
virus  and  Dengue  virus.  With  the  help  of  genome  sequencing  studies,  it  has  been 
possible to determine the various genotypes of JEV in circulation in different geographic 
areas. The two common Indian Genotypes [GP78 and Vellore P20778] show genetic 
similarity to Chinese SA14 and Beijing Genotypes.
Communicability and transmission
JE is a Zoonotic viral disease. JE virus has a complex life cycle. In nature, JE 
virus is maintained in animals and birds, particularly pigs and Ardied birds (e.g., Cattle 
egrets, pond herons etc.).The virus does not cause any disease among its natural hosts 
and the transmission continues unnoticed through mosquitoes. It is carried by female 
mosquitoes from infected pigs or water birds like pond herons and ducks to susceptible 
children.  The  main  vector,  Culex  Mosquitoes  (Culex  tritaeniorhynchus,  C.vishnui, 
C.pseudovishnui and others totally 8 species) live in rural rice growing and pig-farming 
regions. The mosquito breeds in flooded rice fields, marshes, and standing water around 
planted fields. This is the reason why JE is mostly a rural disease.
JE is a seasonal disease. Epidemics coincide with the monsoon and post monsoon 
period (August to December) in Tamilnadu & agricultural pratices, during this period, 
due to high density of the mosquito vector because of stagnant water and presence of 
reservoir host (pigs).
Pigs are the most important reservoirs. Though they do not manifest the disease, 
they develop very high titers of virus in circulating blood and infect mosquitoes. Thus 
pigs are the amplifying hosts.  Susceptible children are infected by infected mosquito 
bites.  After  mosquito bite,  disease appears in  5-16 days.  The virus then invades the 
central nervous system and cause disease. Although infection in human is incidental, the 
virus can cause serious neurological disease with high morbidity and mortality. Infection 
during  the  first  six  months  of  pregnancy  may  result  in  infection  of  the  fetus  and 
miscarriage.
JE does not spread from child to child or from cattle to humans because of the low 
and transient viremia. This is the reason why an increase in cattle and pig   ratio may 
reduce the risk of JE in humans [mosquito bites are shared by cattle and pigs].
Clinical manifestation
The incubation period in man following a mosquito bite varies from 4-14 days. 
Not all individuals bitten by mosquitoes develop disease. The ratio of overt disease to 
inapparent  infection  varies  from  1:300  to  1:1000.  Encephalitis  due  to  JE  shows  a 
scattered distribution. The course of disease in man may be divided into  prodromal, 
acute, late stage and sequele phase. The fatality varies between 20-40 percent, but may 
reach over 58 percent. The average period between the onset of illness and death is 9 
days.
An etiological  diagnosis  of  JE is based on serological  testing using Elisa  that 
detects specific IgM in the CSF or in blood of almost all patients within 4-7 days of 
onset of disease.  
Protective immune response
Protection is associated with the development of neutralizing antibodies. Although 
no internal standard has yet been established, neutralizing antibody titers of 1:10 or more 
are commonly accepted as evidence of protection.  
Treatment
Once a person becomes sick with JE, there is no treatment that can be used to cure 
the patient.  Antibiotics do not work against viruses, and no anti virals are effective. 
Because  there  is  no  specific  therapy  for  JE,  attention  is  given  to  prevention  of 
complications.  
Control programs
Spraying mosquito habitates with insecticides, use of bed nets, and pig control have 
not yielded the desired results. Human vaccination is the only method that has proven 
effective in the control of JE.   
JE IMMUNIZATION   
Scientific evidence for JE immunization
 Human   vaccination has been the only reliable tool   to control JE. Thailand, for 
example,   for many years attempted to control mosquitoes and to respond to outbreaks, 
but it was not until JE vaccine was introduced into the country that the incidence of JE 
fell   dramatically.  
    
There is compelling evidence that human immunization is effective for controlling 
JE. 
Studies in Korea, Thailand and Japan showed >99% reduction in JE cases after 
immunization. 
JE  vaccination in India
In the past attempts have been made in India to vaccinate children against JE. 
However  inadequate  availability  of  JE  vaccine  has  limited  the  campaigns  to  small 
geographical  areas.  Though  there  has  been  a  dramatic  reduction  in  the  case  load 
immediately following these vaccination campaigns, however due to lack of sustained 
vaccination program there has not been any major impact in controlling the disease.
Following sustained JE vaccination in Perambulur district of Tamil Nadu since 
1995 and in the high risk villages of Andhra Pradesh since 1999 there has been some 
impact in reducing the case load and disease incidence in these areas. 
           Following the massive outbreak of JE in 2005 in the districts of Eastern Uttar 
Pradesh and adjoining districts of Bihar, Vaccination campaigns were carried out in 11 
highest risk districts of the country in 2006. Children between the age group of 1 to 15 
years were vaccinated with a single dose of SA 14-14-2 vaccine. 
Summary of JE vaccines available or under development
Source; WHO, October 2006
Cumulative district JE vaccination coverage was as follows
The second year of the government’s five year strategy targets 23 districts of 9 
states.  JE vaccination Campaigns kicked off in March 2007 and by July2007, 20 million 
more children and adolescents were targetted to be immunized against JE. 
Since during 1997, the mosquito pool from Virudhunagar District was confirmed 
to be positive for JE virus and the past history had shown that very high number of cases 
and deaths due to JE were reported in this district.  Hence there was every threat to roll  
back the virus activities in the younger generation who were not protected now in the 
area  for  JE  virus.  So,  Virudhunagar  District  was  selected  for  Japanese  Encephalitis 
vaccination programme during the year 2007.  
VIRUDHUNAGAR DISTRICT
INCIDENCE OF JE
YEAR 91 92 93 94 95 96
97 
& 
98
99
2000 
To 
2005
2006 2007
No. of Cases 18 1 11 7 10 48 0 4 0 1 3
No. of Deaths 8 1 9 7 8 18 0 2 0 1 1
The vaccination was completed in Virudhunagar District during August 2007. 
REVIEW OF LITERATURE
PREVALENCE AND GEOGRAPHICAL DISTRIBUTION
Igarasi .A, 1992,,Burke et al 1998,Umenai et al 1985,   in their articles stated that 
Japanese  encephalitis  (JE),  a  mosquito-borne  flaviviral  infection,  is  the  leading 
recognized cause of childhood encephalitis in Asia.  Approximately 35,000 cases and 
10,000 deaths are  reported annually,  but  in  many locations the disease  is  not  under 
systematic surveillance, and official reports undoubtedly under estimate the true number 
of cases. 1-3
The mosquito-borne mode of JE transmission was elucidated with the isolation of 
JE virus from Culex tritaeniorhynchus mosquitoes in 1938, and subsequent field studies 
established the role of aquatic birds and pigs in the viral enzootic cycle. 
Hiroyama  T,  1962,  in  his  article  mentioned  that  summer-fall  encephalitis 
outbreaks consistent  with JE were recorded in Japan as early as 1871, of which the 
largest, in 1924, led to more than 6000 cases, 60% of them fatal.4
Carey  DE,  et  al  1969,  Banerjee  K,  1994,  in  their  articles  stated  that  JE 
transmission was first recognized in Southwest Asia after an outbreak occurred in 1948 
in  Sri  Lanka.   Sporadic  cases  and  later  epidemics  were  recognized  on  the  Indian 
subcontinent around Vellore.  8,9  The disease  is currently recognized to be hyperendemic 
in Northern India and Southern Nepal, Central India (Andhra Pradesh), and Southern 
India (Goa, Karnataka, and Tamil Nadu)
Service  MW,  1991  in  his  article  described  that  the  apparent  spread  to  or 
amplification of JE in new areas has been correlated with agricultural development and 
intensive rice cultivation supported by irrigation schemes.10
CLINICAL  ILLNESS
Halstead SB et al, 1962, Gajanana et al, 1995 in their articles stated that the great 
majority  of  infections  are  not  apparent,  and  only  1  in  250  infections  results  in 
symptomatic illness.  11,12  The principal clinical manifestation of illness is encephalitis, 
and milder clinical presentations, such as aseptic meningitis and simple febrile illness 
with headache, usually escape recognition. 13,22
   
CONGENITAL INFECTION
Bhonde  RR  et  al  1985,  in  their  study  observed  that  human  placental  organ 
cultures, obtained from medically terminated pregnancies at 8 to 12 weeks’ gestation, 
supported JE viral replication, but tissues from full-term pregnancies were resistant to 
infection.26
Ogata A et al 1991, Kimura-Kuroda J 1993, in their   experimental studies have 
shown that JE viral neurotropism is related to neuronal immaturity. 27,28 
VIROLOGY 
Kuno G et al 1998, Chambers TJ et al 1990, stated that   JE virus is one of 70 
viruses in the Flavivirus genus of the Flaviviridae family29,30 
Murphy PA 1980, in his article mentioned that the complete genomic sequences of 
JE virus and several other flaviviruses have been determined, including yellow fever 
(YF)  virus,  the  prototype  virus  in  the  family.   Morphologically,  flaviviruses  are 
spherical, approximately 40 to 50 nm in diameter, with a lipid membrane enclosing an 
isometric  30-nm-diameter  nucleocapsid  core  comprising  a  capsid  (C)  protein  and  a 
single-stranded messenger (positive) sense viral RNA.31
Sumiyoshi H, et  al  1987, Nitayaphan S et al,1990, in their  articles stated that 
membrane   surface  projections  are  composed  of  a  glycosylated  envelope  (E)  and 
membrane (M) protein, a mature form of the premembrane (prM) protein. JE viral RNA, 
10,976 bases in length, encodes an uninterrupted open reading frame (ORF), flanked by 
95 and 585 base untranslated regions at the 5’ and 3’ ends, respectively. 32,33
The E glycoprotein is the major virion antigen responsible for virion assembly, 
receptor  binding,  membrane  fusion  and  elicitation  of  virus-neutralizing, 
haemagglutination inhibiting, and anti-fusion antibodies. The E protein is the principal 
target for neutralization in vitro and in vivo by specific antibodies (Gould et al, 1986; 
Hawkes et al, 1988;Kimura -Kiroda  and Yasui, 1988).   
          NS1(Non structural 1 protein) is believed to be involved in the assembly and 
release of virions (Lee et al, 1989).NSI protein evokes a strong antibody response that 
protects the host against challenge with flavivirus (Schlensinger et al,1987). 
Rupinderjeet    kaur et al, 2003 in their study found that the prM, E, NS1 proteins 
are the most effective candidates for inducing protective immunity against JEV.144.
PATHOGENESIS
Johnson RT,et al,1985,Hase T,et  al,1990,Dropulic B,et  al,1990, in their articles 
stated  that  after  an  infectious  mosquito  bite,  viral  replication  occurs  locally  and  in 
regional lymph nodes.  Virions disseminate to secondary sites, where further replication 
contributes to an augmented viremia.  Invasion of the CNS probably occurs from the 
blood by antipodal transport of virions through vascular endothelial cells. 23,40-42. 
The pathogenesis of JE encephalitis appears to be a combination of direct, virally 
mediated  damage  and  the  host  inflammatory  response.  The   host  immune  response 
comprises antibody mediated immunity, particularly against the E and NS1 proteins, cell 
mediated immunity, including  cytotoxic T lymphocytes (Johnson et al,1985;Konishi et 
al,1995),and apoptosis(Jan et al,2000; Liao et al ,1997; Parquet et al 2002).146,147 
DIAGNOSIS
Inada  R,et  al,1937,Innis  B,  et  al,1995,Burke  D  Set  al,  1985,Kedarnath  N  et 
al,1984,in their article mentioned that although a history of exposure to an endemic area 
and  certain  clinical  features  may  suggest  JE,  clinical  diagnosis  is  unreliable,  and 
laboratory confirmation, usually by serological tests, is necessary.  JE virus occasionally 
can be recovered from blood in the pre neuro invasive phase (up to 3 to 7 days after 
onset), but patients presenting with encephalitis usually are no longer viremic13, 24,67
The  text  book  VACCINES  3rd vol  by  Plotkin,Orenstein   states  that  JE  virus 
produces cytopathic effects  in  Vero,  LLCMK2,  and PS cells  and kills  suckling mice 
inoculated  intracerebrally.  C6/36  and  Ap61  mosquito  cell  lines  and  T.  splendens, 
inoculated intrathoracically, also are sensitive systems for viral isolation.  Viral isolates 
are  readily  identified  by  immunofluorescent  (IF)  techniques  using  virus  specific 
monoclonal antibodies or by neutralization. 
Burke DS et al,  1985, Innis BL,et al,1989 in their studies found that the most 
widely  used  diagnostic  method  is  IgM-capture  enzyme-linked  immunosorbent  assay 
(ELISA)  25,  69  Specific IgM can be detected in CSF, serum, or both in approximately 
75% of patients within the first 4 days after onset of illness , and nearly all patients are 
positive 7 days after onset.  Both fluids should be tested to maximize sensitivity.  A 
specific diagnosis also can be confirmed by demonstrating fourfold or greater changes in 
antibody titer by conventional serological procedures (e.g., hemagglutination inhibition, 
complement fixation, IF antibody, ELISA, or neutralization).  Heterologous flaviviral 
antibodies (e.g., to dengue and West Nile viruses) are a potential source of false-positive 
reactions. 
Konishi   E et al 1996, in his study demonstrated that synthetic antigens, including 
recombinant virus-like particles expressing the viral E protein, are a potential source of 
standardized antigen with improved specificity.70
EPIDEMIOLOGY
IgarashiA,1992, BurkeDS,et al,  InnisB, 1995, RosenL, 1986, SchererWF, et al, 
1959,  in  their  articles  showed that  JE is  transmitted  in  epidemics or  in  an  endemic 
pattern, or both, in virtually every country of Asia.  JE is principally a disease of rural 
areas  in  which  vector  mosquitoes  proliferate  in  close  association  with  pigs,  wading 
birds, and ducks, the principal vertebrate amplifying hosts (Fig. 27-9) 1,2,1371,72. 
Gould DJ et al 1964, Wang YJ etal 1982 in their studies found that humans and 
horses may become ill after infection, but such illness is incidental to the transmission 
cycle73,74
RosenL,1986,  SchererWF  et  al,1959,  in  their  article   mentioned  that  Culex 
tritaeniorhynchus is the principal JE vector in most areas of Asia, but various principally 
ground  pool  and  rice  paddy-breeding  species,  including  Culex  vishnui,  Culex 
pseudovishnui,  Culex  gelidus,  Culex  fuscocephala,  Culex  bitaeniorhynchus,  Culex 
infula, Culex ubitmorei, and Culex annulus, are also important locally. 71,72. 
Bista MB et al,2001 in their articles stated that the Haem-agglutination inhibition 
test was done on human and animal serum during 1978 to 1980 in Nepal .It has shown 
that pigs and ducks are main reservoir hosts.143.
Takahashi  K et al 1972, in his article mentioned that JE mosquito vectors are 
zoophilic; Consequently, cows and certain other animals can reduce risk to humans by 
diverting vector mosquitoes (zooprophylaxis). 75.
J.  Commun  .Dis.35(1)2003:40  in  a  study  on  a  focal  outbreak  of  Japanese 
Encephalities  among horses in Pune District  India  also confirmed the zoophilic nature 
of the vectors. 
Takahashi K et al1972, Sasaki  O et al 1982, Vaughn DW et al 1992, in their 
studies found that immunizations of pigs prevents abortion and stillbirths and also may 
reduce viral transmission by nullifying the role of pigs as viral amplifiers. 75-77
Takahshi K et al 1972, in their study explained that experimental immunization of 
nearly the entire pig inventory on one island led to a significant reduction in human 
cases.75
ACTIVE IMMUNISATION
INACTIVATED MOUSE BRAIN DERIVED JE VACCINE
 The text book VACCINES 3rd vol by Plotkin, Orenstein, states that Mouse brain-
derived  vaccines  are  produced  in  Japan  and  elsewhere  using  a  similar  sequence  of 
centrifugation, ultrafiltration, protamine sulfate precipitation, and formalin inactivation 
in  the  cold,  followed  by  further  purification  by  ultrafiltration,  ammonium  sulfate 
precipitation, and continuous zonal centrifugation on sucrose density gradients.  
Oya A 1998 in his article mentioned that in most areas of Asia, vaccine produced 
from the Nakayama strain is given subcutaneously in two 0.5/mL doses 1 to 4 weeks 
apart (1.0 mL for people >3 years of age) usually  beginning at  the age of 12 to 36 
months, with a booster dose at 1 year and additional booster doses thereafter at 1- to 3-
year intervals.83
Immunogenicity  studies  in  subjects  from  areas  without  endemic  transmission 
(Western countries and areas of India) indicate that three doses are necessary for an 
adequate antibody response. 80,92-94
The U.S. Public Health Service (Advisory Committee on Immunization Practices) 
(ACIP) recommends three doses, on days 0, 7, and 30. 95
INACTIVATED   PHK CELL   DERIVED JE VACCINE
Gu PW,et al ,1987 , in  their article reviewed that inactivated JE vaccine prepared 
from the P3 strain in PHK cells is produced exclusively in the PRC and has been that 
country’s principal JE vaccine since 1968. 82
 Zhang  XC et  al,  1990,  in  their  article  explained  that  concurrent  JE  vaccine 
administration  did  not  lead  to  significant  changes  in  responses  to  measles  or  DPT 
antibody titers or in the size of BGC reactions.96
LIVE ATTENUATED JE VACCINE
Attenuated JE viral strains have been sought by passaging wild strains serially in 
various cell  culture systems, including PHK, chick embryo, and embryo mouse skin 
cells. 97-100.
Ni  H ,  et  al,  1998 in  their  article  found  that  loss  of  neurovirulence  in  mice, 
hamsters, or pigs, or any combination of the three, initially suggested the possibility of 
safe use in humans. Attenuation may be correlated with decreased binding to mouse 
brain cell receptors. 101   
Wang SG ,et al 1990 in their studies described that several hundred ampoules of 
seed virus, prepared from the seventh passage level of SA14-14-2 virus, are maintained 
in lots at the NICPBP in Beijing.107
Wang SG et al 1990 in their studies showed that the infectious titer of lyophilized 
vaccine  is  not  appreciably  changed after  storage  at  37oC for  7  to  10  days,  at  room 
temperature for 4 months, or at 4 to 8oC for at least 1.5 years.  After reconstitution with 
sterile saline or distilled water and storage at 23oC, the vaccine’s infectious titer is stable 
for 2 to 4 hours or 2 hours, respectively.107
Yu YX , et al ,1989, in their studies found that attenuated vaccine provided more 
effective protection than inactivated  P3 vaccine against a spectrum of JE strains isolated 
in China.108
Chen  BQ et  al  1982  in  their  article  stated  that  the  virus  did  not  revert  to  a 
neurovirulent phenotype after mosquito passage.  120.    A 0.5 mL dose is administered 
subcutaneously to children at  1 year of age and again at  2 years.   In some areas,  a 
booster dose is given at 6 years. 
Zheng-Le Liu et al, 1997 in their article stated that the short term safety of both 
the  SA -14-14-2  virus  strain  and  of  hamster  kidney  cells  as  a  substrate  for  the 
manufacture of live attenuated vaccines has been well documented. 141
Tsai  TF  et  al  1998  in  their  studies  mentioned  that  a  more  conventional 
administration schedule in which the two primary doses were given at intervals of 1 or 
2.5 months was shown to produce immunity in 94 to 100% of immunized school-aged 
children122.
EXPERIMENTAL VACCINES
Several  candidate  JE  vaccines  are  in  various  stages  of  early  clinical  and 
preclinical development or research.123
The most extensively evaluated candidate vaccines have been a recombinant virus 
pair engineered by inserting four JE viral genes (prM, E, NS1, and NS2a) into attenuated 
vaccinia (NYVAC) or canarypox (ALVAC) viruses, Yellow Fever 17D viruses.  These 
recombinants expressed the encoded JE structural and nonstructural gene products and 
stimulated JE protective antibodies in mice.
Fu DW,etal, 1996 in their studies stated that adaptation of the SA14-14-2 strain to 
insect cells has been reported to improve propagation.124
Konishi E, et al 1997 in their studies found that the best-characterized candidate 
subunit vaccine is a vaccinia-JE virus recombinant that releases extracellular particles 
(EPs)  composed  of  JE,  prM,  and  E  proteins  in  an  apparently  more  authentic 
configuration than when presented as simple peptides. 125
PROTECTIVE EFFECTS OF IMMUNIZATION
C.V.R.Mohan Rao et al, 1993 in their study mentioned that the serum antibody 
titres  were  determined  by  mouse  neutralization  test  (MNT),  plaque  reduction 
neutralization  test  (PRNT)  and  haemagglutination  inhibition  test  (HI).  From  the 
results ,MNT appeared to be the most sensitive of  the three tests followed by  PRNT, 
HI.
INACTIVATED MOUSE BRAIN   DERIVED JE VACCINE:
A neutralizing antibody titer of more than 1:10 generally is accepted as evidence 
of  protection  and  postvaccination  seroconversion.   Passively  immunized  mice  that 
acquire this level of neutralizing antibody are protected against challenge from 105 LD50 
of JE virus, a typical dose transmitted by an infectious mosquito bite.  Among Asian 
children immunized with two doses of Nakayama or Beijing-1 strain-derived vaccines, 
neutralizing antibody responses to the respective homologous vaccine strains are in the 
range of 94 to 100%; Responses to strains representing a heterologous antigenic group 
are  lower .  126-128
The  proportion of vaccinees  retaining detectable neutralizing antibodies and their 
Geometric Mean Titres ( GMTs ) declined rapidly in the year after the primary two-dose 
series,  so  that  only  78 to  89% of  Nakayama vaccine  recipients  and 88 to  100% of 
Beijing-1  vaccine  recipients  still  had  protective  levels  before  the  scheduled  1-year 
booster.  Antibody persistence was greater among Beijing-1 vaccine recipients.  After 
booster immunization (third vaccine dose) antibody response rates were uniformly high 
(100%).  Where the influence of previous flaviviral infections was unlikely, vaccinees 
receiving two doses  produced lower  seroconversion  rates  and lower  GMTs  20,  221-223. 
Moreover, as rapidly as 6 to 12 months after primary immunization with two doses, 
neutralizing antibody titers declined below 1:8 in 90% of vaccinees.181  A three-dose 
primary schedule was more immunogenic, resulting in seroconversion rates exceeding 
90% and significantly higher neutralizing antibody titers. 9, 92-94
Hoke  CH  ,et  al  1988  in  their  article  stated  that  results  of  the  efficacy  trial 
comparing  a  monovalent  Nakayama  strain  vaccine  with  a  bivalent  vaccine  also 
containing Beijing-1 antigen showed that the two were equally efficiacious. 129
Neutralizing activity may be present below the threshold of detection in in vitro 
assays, and T-cell memory may have been established in vaccinees who appear to be 
seronegative, providing sufficient help to clear infections upon reexposure. 
Hoke  et  al    immunized  43,708  Thai  children  with  JE  vaccine  (Biken)  and 
administered tetanus toxoid vaccine to another 21,516 chilren, who served as a control 
group .Protective  efficacy in the JE vaccine group was 91%, and the group receiving JE 
vaccine also showed a trend toward fewer and less severe cases of dengue fever.129
Studies  in  Asia  to  determine  the  persistence  of  vaccine-derived  immunity  are 
complicated by natural infections with dengue, West Nile virus, or other flaviviruses and 
reexposure to JE virus itself, all of which act to reinforce and broaden vaccine-derived 
immunity to JE virus.38,39,43-66,69
Poland JD et al 1990, Kanamitsu M, et al 1970, in their studies found that even 
with  the  potential  for  these  reinforcing  infections,  several  studies  in  Asian  and  in 
Western subjects indicate a progressive decline in antibody levels in the first year after 
primary immunization with two doses. 80, 84
Cross-sectional  sero  surveys  in  Japan  and  Taiwan  indicate  a  rapid  decline  of 
immunity  in  childhood.   Observations  of  vaccine  efficacy  in  the  Taiwan  field  trial 
parallel these results: In the second year after immunization, protective efficacy declined 
from 80 to 55% (95% confidence interval (CI) = 39-75%).130
Gowal  D,  et  al  1995  ,  in  a  small  study  of  vaccinees  receiving  an  Indian-
manufactured JE vaccine found that 34 of 35 (97%) retained neutralizing antibodies 3 
years after a primary series of three doses, and 31 of 34 (91%) retained antibodies at 4.5 
years, with GMTs of 71 and 32, respectively.  However, the boosting effect of naturally 
acquired flaviviral infections in these subjects cannot be ruled out. 131
INACTIVATED   PHK   CELL   DERIVED VACCINE
Gu  PW  et  al  1987,  Ren  YL  1982  in  their  studies  showed  that  Extensive 
raindomized field trails among 480,000 children have demonstrated vaccine efficacies in 
the range of 76 to 95%. 82, 133.   These observations suggest that clinical efficacy is better 
than the reported protective efficacy. 82
L IVE   ATTENUATED   JE VACCINE
More than 200 million doses of  this  SA-14-14-2 vaccine have been delivered 
since  1988  with  excellent  record  of  safety  and  efficacy  (Xin  et  al,1988;Liu  et 
al,1997;Bista et al 2001).  Other   countries that have licensed and used the vaccine are 
South Korea( since 2001),Nepal (since 1999), and India (since 2006).(PATH).
Prequalification and licensing
The manufacturer is preparing a file for submission to WHO for prequalification 
of the SA-14-14-2-vaccine.WHO prequalification enables procurement of product by 
United Nations agengies. It is anticipated that the vaccine will be prequalified by 2009. 
WHO prequalification is not a   requirement for use of the vaccine;   A country can 
individually license the vaccine through its own national regulatory authority. (PATH- 
April 2007).
After a single dose, antibody response are produced in 85 to 100% of non immune 
1 to 12year old children,  with a response gradient  that  parallels progressive vaccine 
dilution. 105,106,134,135
 Because of variable immune response rates after one dose, SA14-14-2 vaccine is 
given  in  a  schedule  of  two  doses  separated  by  a  year,  according  to  the  custom of 
administering JE vaccines in annual spring compaigns.   The immunogenicity of two 
doses  given  at  intervals  of  either  1  or  2.5  months  was  shown in  12  to  15year  old 
children.  Response rates were similar: 75 to 100% after one dose and 94 to 100% after 
two  doses  (two  vaccine  lots  were  compared),  but  there  was  a  trend  toward  better 
seroconversion with the longer interval, and GMTs were approximately two-fold higher 
(65-89 versus 115-158, respectively).  If these results can be confirmed in infants, the 
SA 14-14-2 vaccine could be integrated into a routine childhood immunization schedule, 
potentially improving vaccine coverage.122.
Efficacy  trials  in  children  1  to  10  years  old  have  consistently  yielded  high 
protection rates above 98%.  114,136,137
SIDE EFFECTS OF IMMUNISATION
Inactivated Mouse Brain Derived JE Vaccine
Local tenderness, redness, or swelling at the injection site  occur in approximately 
20% of individuals immunized with inactivated mouse brain-derived vaccines.  Mild 
systemic  symptoms,  chiefly  headache,  low-grade  fever,  myalgias,  malaise,  and 
gastrointestinal symptoms, are reported by 10 to 30% of vaccinees.  80, 93,94, 126
In  a  prospective  study  among United  States  military  personnel  in  Japan ,  the 
overall  allergic  reaction  was  0.6%  (Japanese  encephalitis  vaccine.  Weekly 
Epidemiological Record,1998). 
An  important  feature  of  the  reactions  is  the  potential  for  delayed  onset, 
particularly after a second dose.  In a prospective study of 14,249 U.S. Marines, the 
median interval between immunization and onset was 18 to 24 hours after the first dose, 
with 74% of reactions occurring within 48 hours. 80,81, 139.   
LIVE ATTENUATED JE VACCINE
  LiuZL, et al, 1997,in their study found that a block randomized cohort study of 
13,266  vaccinated  and  12,951  nonvaccinated  1  to  2  year-old  children  followed 
prospectively for 30 days confirmed the vaccine’s safety.  No cases of encephalitis or 
meningitis were detected in either group, and  rates of hospitalization; new onset of 
seizures; fever lasting more than 3 days; and allergic, respiratory, and gastrointestinal 
symptoms were similar in the two groups.  The observations excluded a vaccination-
related encephalitis risk above 1 in 34..141
INDICATIONS   FOR   IMMUNISATION
The  text  book  VACCINES  3rd vol  by  Plotkin,Orenstein  states  that  Universal 
Primary immunization is indicated for children between 1 and 2 years of age.  The peak 
risk of infection is in children between 1 and 4 years of age, which may reflect the 
waning protective effects of maternal immunity and patterns of outdoor activity that 
place young children at risk.  However, cases occur in children through the first decade 
of  life,  and  in  most  areas  with  risk  of  enzootic  transmission,  immunity  should  be 
maintained by boosters through the age of 10 years. Immunization is recommended for 
visitors to epidemic or endemic areas during the transmission season, especially when 
there will be an extended period of exposure (more than 30 days) or the individual is at  
high risk of exposure to vectors.
Ramakrishna and colleagues, 1999, showed that oral immunization of mice with 
live JEV induced a brisk protective immune response (76.7% protection with mouse 
brain  derived  immunogen  and  70%  with  cell  culture  derived  immunogen)  against 
subsequent intra cranial challenge.148.
AIMS & OBJECTIVES
“The study on  Efficacy and Safety of  SA-14-14-2  vaccine against Japanese 
Encephalitis  Virus   at  Virudhunagar District”  conducted  from October  2007  to 
December 2007 in 60 school going children  in the age group of 6-10 years was aimed. 
• To know the prevaccination titre of JE antibodies in the study population. 
• To study the efficacy of the vaccine 
a) By demonstrating seroconversion in the vaccinees by standard techniques 
like Haemagglutination Inhibition Test and Mouse Neutralisation Test. 
b) By Case Study. 
• To study the safety of the vaccine by observing systemic toxicity and Local reaction. 
MATERIALS AND  METHODS
A total of 60 children in the age group of 1to 15yrs, belonging to 5 schools in 5 
blocks (12 from each) of Virudhunagar District of Tamilnadu were vaccinated after a 
Physical examination for fitness, and after ruling out contraindications. A total of 178 
blood samples were collected from them, 3 samples from each child, one sample prior to 
vaccination,  one  sample  4  weeks  after  vaccination  and  one  sample  12  weeks  after 
vaccination. Two postvaccination samples from one child was not collected .
This is an interventional type of study, in a randomized sample collection with an 
aim  to  study  the  prevention,  Safety  and  Efficacy  to  determine  the  outcome  of 
immunogenicity of JE live attenuated SA-14-14-2 Vaccine.  
This study was conducted at the WHO Acute Meningo Encephalitis Syndrome 
Laboratory, Institute of Microbiology, Madurai Medical College, Madurai.  The study 
period was 3 months from October 2007 – Dec. 2007.  The study population included 60 
children vaccinated against Japanese Encephalitis, of 6-10 years age groups.  The total 
sample size was 178 serum samples. 
Written informed consent was obtained from the Parents/Guardian of vaccinated 
children.  Ethical Clearance was obtained from the college Human and Animal Ethical 
Committees.
Eligibility Criteria 
Inclusion Criteria 
• 1-15 years of age group in both sexes.
• Person without fever / malnutrition / acute infectious disease. 
• Person without active untreated tuberculosis 
• Person without any systemic disease.
•  Person without any allergy & Convulsions.
• Person not on any immunosuppressive therapy.
• Person without any H/o hypersensitivity.
• Person without a history of immunization with any other live attenuated vaccine 
within the past one month. 
Exclusion Criteria 
• Acute infectious disease
• Tympanitis
• Cardiac, liver, Kidney diseases.
• Person with a proven or suspected hypersensitivity .
• Person on immuno suppressive therapy
• Known or suspected impairement of immunologic function.
• History of serious chronic disease. 
• Acute medical illness with or without fever within last 72 hours or an axillary 
temperature > 37.5oC at the time of inclusion. 
• History of documented and suspected encephalitis, encephalopathy, meningitis. 
• Immunization with JE vaccine prior to enrollment. 
• If received any vaccine, other than the study vaccine within 4 weeks prior to or 
scheduled to receive a non study vaccination during the conduct of this trial. 
• History of seizures including history of febrile seizures, or any other neurologic 
disorder. 
Vaccine 
Live attenuated  SA 14-14-2  JE Vaccine  manufactured in  Chengdu Institute  of 
Biological Products,  Chengdu, CHINA, was used for vaccination.  This vaccine was 
supplied in 5 dose vials as a lyophilized powder and was reconstituted with 2.5ml of 
sterile diluent (PBS ).  After reconstitution, it turns into a transparent Orange, red or light 
pink  liquid.   The  reconstituted  vaccine  was  used  within  2  hours  of  reconstitution. 
Vaccine was stored and transported between 2oC to 8oC and protected from light. 
Schedule 
One dose (0.5ml) contains not less than 5.4 log PFU of live JE virus. The vaccine 
was injected subcutaneously in the upper arm of children of 1-15   years of age. Sterile 
water was used for cleansing the skin before injection.  The vaccine was administered in 
the 1st week of August 2007. The children were followed up for 5 days for side effects or 
reactions.                                                                                        
Blood  Specimens 
Blood samples of 60 children were collected approximately 1 week prior to the 
vaccine to determine   their antibody status to JE virus. These samples were treated as 
prevaccination samples.   The samples were again collected approximately 4 weeks & 
12 weeks after the vaccination. 
Collection & Storage of Blood Specimens 
All the blood specimens (5-10 ml each) were collected by vene puncture.  Serum 
was  separated  within  48  hours  and  the  sera  were  stored  on  wet  ice  till  they  were 
transported  to  Madurai  Medical  College,(MMC),  Institute  of  Microbiology,  WHO 
AMES LAB, Madurai  which is situated at a distance of 50 km from Virudhunagar. At 
MMC, the sera were stored at minus 20oC till testing. 
Processing                                                                                                                          
I. Pre and post vaccination samples were screened for antibodies to the JE virus by 
MAC ELISA by NIV PUNE KIT. 
II. The antibody titre in the pre and postvaccination samples were determined by  the 
haemagglutination inhibition test using suckling mice brain as antigens which was 
prepared inhouse.  
III. The  samples  were  also  tested  for  presence  of  neutralizing  antibodies  by  the 
Neutralization test in mice (MNT) 
Test Procedures 
A) MAC ELISA
Procedure of the assay 
IgM antibodies in the vaccinees blood are captured by Anti-human IgM (µ chain 
specific) that are coated on to the solid surface (wells).  In the next step, JE antigen is 
added which binds to captured IgM, if the IgM and antigen are homologous. Unbound 
antigen  is  removed  during  the  washing  step.  In  the  subsequent  step,  Biotinylated 
flavivirus cross reactive monoclonal antibody (Hx-B) is added followed by Avidin-HRP. 
Subsequently, substrate / chromogen is added and watched for development of colour. 
The reaction is  stopped by I  N H2SO4.    The intensity  of  color  /  optical  density  is 
monitored at 450 nm.  OD readings were directly proportional to the amount of JE virus 
specific IgM antibodies in the sample. 
Test Protocol 
1) The serum samples were diluted 1:100 with sample dilution buffer. 
2) The coated wells were washed thrice with wash buffer. 
3) 50µl  of  diluted  samples  were  transferred  to  the  appropriate  wells.   50  µl  of 
positive & negative controls were added to respective wells. 
4) The plate was kept in humidified box & incubated at 37oc for 1 hour. 
5) At the end of incubation, the plate was washed 5 times with wash buffer.  The 
plate was tapped after last wash on a tissue paper. 
6) 50  µl  of  JE  antigen  was  added  to  each  well.   The  step  4  &  5  were  
  repeated. 
7) 50 µl of biotinylated monoclonal antibody was added to each well.  The step 4 & 
5 were repeated. 
8) 50 µl Avidin-HRP was added to each well.  The plate was kept in a humidified 
box and incubated for 30 minutes at 37oc.  The step 5 was repeated. 
9) 100 µl of diluted substrate was added to each well. 
10) The plate was incubated at room temperature for 10 minutes. 
11) The reaction was stopped with 100 µl of 1 N H2SO4. 
12) The absorbance was measured at 450nm within 10 minutes. 
Quality Control 
Each kit was supplied with one Positive control and one Negative control.  These 
were mainly  used for validation of the kit. 
Expected values are given below
Positive  : OD values > 0.5
Negative : OD value < 0.18
Interpretation of the results 
1. If OD value of sample tested exceeded OD of Negative control by a factor 2.1 
(Sample OD >  Negative OD x 2.1), the sample was considered as “Positive”. 
B) HAEMAGGLUTINATION AND HAEMAGGLUTINATION 
     INHIBITION TESTS 
Principle 
Various animal viruses have the property to adsorb to red blood cells.  It usually 
results in agglutination of these cells.   This haem agglutination (HA) test provides a 
fairly quantitative and easy method of detection, identification and titration of virus. 
This  haemagglutination  can  be  inhibited  by  specific  antiviral  antibody.   This  haem 
agglutination inhibition (HI) has been employed as an assay method for detecting viral 
antibody titres. 
The antigen used in this test was prepared in the lab by inoculating the seed virus 
into the brain of suckling mice.
Procedure for JE antigen extraction 
5 litters of suckling mice were inoculated each by intracerabral route with 0.02ml 
of the JE seed virus using a 0.25ml tuberculin syringe and ¼” 27 G needle.  The mice 
were  observed  daily  for  21  days.  The  mouse  with  symptoms  were  recorded  using 
standardized abbrevations as follows : 
M  - Missing
   Pr  - Prostrate
E   - Eaten by mother
W  - Weak
D   - Dead
S    - Sick
Pa   - Paralysed
Co   - Convulsions
The mice showing definite signs of infection were sacrificed by brief exposure to 
chloroform fumes. 
The brains of the sick and dead mice were harvested & stored at minus 700C. 
The brains were ground with borate saline by using mortar and  pestle and was 
centrifuged at 10,000 rpm for 15 mts. 
The antigen was sonicated and to this, protamine sulphate (for 1ml antigen – 3mg 
protamine sulphate) was added & refrigerated overnight. 
This antigen was centrifuged for 15 mts at 3000 rpm in the cold. 
This antigen was used for HA & HI tests. 
PREPARATION OF GOOSE ERYTHROCYTES AND THEIR WORKING 
SUSPENSION  
i) 0.5ml of goose blood was collected aseptically from wing vein in 1.5ml of acid 
citrate dextrose (ACD) solution. 
ii) One volume of whole blood was mixed with 2.5 volume of dextrose gelatin veronal 
(DGV) solution and was centrifuged at 1,500 rpm for 15 minutes at +4oC.
iii) Packed cells were resuspended in normal  saline 3 times the original  volume of 
blood and was centrifuged.  This procedure was repeated three times. 
iv) Packed cells were suspended in normal saline in 3 times the original blood volume 
and stored at +4oC.
v) This was Centrifuged at 2,500 rpm for 6 minutes at room temperature or  +4oC.
vi) The supernatant was discarded.  To packed cells,   0.9 percent NaCl was added for 
suspension and was centrifuged  at 2,500 rpm  for 3 minutes twice   and  for  6  
minutes once . 
vii) Packed cells were suspended in 0.9 percent NaCl to get a 10 percent suspension. 
The optical density was checked with a spectrophotometer. 
viii) The packed cell suspension was stored at +4oC.  
PROCEDURE FOR HAEMAGGLUTINATION TEST 
1) The  microtiter  plate  was  marked  with  a  glass  marking  pencil  giving  different 
dilutions of antigen and was prechilled. 
2) 25µl BABS (Bovine Albumin in Borate Saline) was added upto 10 th well, 11th well 
was left blank, and to the 12th well ,  50 µl BABS was added. 
3) The plate was refrigerated for half an hour. 
4) With the microdilutor, 25 µl of JE antigen was transferred to the 1st well, mixed and 
transferred 25µl from the 1st well to 2nd well, and further 2 fold dilutions were made 
upto 10th well. 
5) Refrigerated for 1 hour.
6) 50 µl of 0.4% goose RBCs was added to all except 11th well. 
7) The plate was shaken gently to mix the reagents and was kept at room temperature 
or 37oC.
8) The test results were recorded after about 60 minutes.
9) Complete agglutination = +
Partial agglutination = (+)
Trace agglutination = (+)
No agglutination = 0
10)  16 units of this antigen was used in HI test. 
PROCEDURE FOR HAEMAGGLUTINATION INHIBITION TEST 
Kaolin Treatment and Erythrocyte Adsorption of Serum 
i) 2 volumes of serum was mixed with 3 volume of borate saline in pH 9 & 5 volumes 
of 25% Kaolin.
ii) This  mixture  was  kept  at  room  temperature  for  20  minutes  with  occasional 
shaking. 
iii) This  was  centrifuged  at  2,500  rpm for  30  minutes  at  room temperature.   The 
supernatant fluid is 1:5 dilution. 
iv)  The kaolin treated sera were chilled in ice bath and 0.1ml packed washed goose 
RBC , was added per 5ml of a 1:5 diluted sera.  
v) This was kept in ice bath for 20 minutes with occasional shaking. 
vi) This was centrifuged for 10-15 minutes at 2000 rpm in the cold.
vii) The supernatant was collected as 1:5 dilution. 
Procedure for Haemagglutination inhibition Test 
1. The microtitre U plate was   Prechilled & marked. 
2. 25µl BABS was added upto 10th well.  11th well was left blank, and to the 12th well , 
50 µl  of BABS was added. 
3. Kept at 4oC for half an hour. 
4. 25 µl of 1 in 5 diluted sera were added to the 1st well with the microdilutor. 
5. Serial 2 fold dilutions. (1:10 to 1:5120) of sera were made with the microdilutor upto 
10th well. 
6. Kept at 4oC for half an hour. 
7. 25 µl of 16 units HA antigen was added to each well. 
8. Kept at 4oC overnight. 
9. 50 µl of 0.4% goose RBCs was added to each well including cell control well (12th) 
10.Kept at room temperature for half an hour. 
11.The titre was read as the highest dilution of the serum which completely inhibited 
agglutination. 
Neutralization Tests in  mice (MNT) 
Titration of JE virus in vivo by intracerebral inoculation 
The infectivity titre of the virus was determined in vivo by inoculating increasing 
dilutions of the virus material to laboratory infant mice and based on mortality seen in 
different  dilutions,  the  infectivity  titre  which  is  the  reciprocal  of  highest  dilution 
showing 50% mortality in the inoculated mice and expressed as LD50/ml was calculated 
by using Reed-Muench formula. 
Procedure 
1) Working in microbiological safety cabinet, the diluting fluid PBS containing 2% 
serum was prepared & dispensed as 9ml in test tubes labelled 10-1 to 10-7.   The test 
tubes were kept in rack immersed in plenty of ice. 
2) To make 10 fold (log) dilutions of the virus material, 1 ml of virus was diluted in 
9ml of diluent to get the initial dilution i.e. 10-1.  Subsequently, 1ml of previous 
virus dilution was transferred to next dilution by using at each step a fresh pipette, 
to achieve serial 10 fold dilutions. 
3) 0.03ml of each virus dilution was inoculated intra cerebrally  into infant  mice, 
starting from the highest dilution (10-7).  At least 6 mice per dilution were used 
and these were transferred into cages appropriately labelled. 
4) The mice were observed for 14 days for specific signs and symptoms of JE.  Any 
death  occurring  within  5  days  should  be  considered  non-specific.    The  total 
number  of  specific  deaths were noted in  each dilution and the virus titre  was 
calculated by using Reed-Muench formula. 
Neutralization tests were carried out using a fixed dose of virus (P20778 strain of 
JE virus) and undiluted serum.  Equal quantities of serum and virus suspension were 
mixed and were incubated at 37oC for one hour and were then inoculated into infant 
mice (0.03 ml) by the intra peritoneal (IP) route. The virus dose varied between 85 to 
360 LD in IP route.  A serum was considered positive for neutralizing (N) antibody if the 
survival ratio in the mouse group inoculated with the respective serum virus mixture was 
between 70 and 100 per cent, partially positive if it was between 31 and 69 per cent and 
negative if it was below 30 per cent. 
The reports of IgM capture ELISA, HI antibody titre and MNT antibody titres 
were  analysed in the  pre immunized and post immunized samples to find out whether 
the JE vaccine given in this district had any immunological  effect in the vaccinated 
children. 
The efficacy of the vaccine was further confirmed by the case study.  The cases of 
JE and deaths reported prior  to  vaccination and post  vaccination were analysed and 
efficacy determined by noting the decrease in the incidence of cases and deaths.  
Further the safety of vaccine was studied by analysing various local reactions and 
systemic toxicity.  In local reactions, symptoms like local tenderness, redness, swelling, 
and  itching were noted.  In systemic toxicity, fever, headache, rash, malaise, nausea, 
vomitting,  diarrhoea,  and  sorethroat  were  noted.   These  signs  and  symptoms  were 
analysed to note if they adversely affected the immunised children.   
RESULTS
During the year 2007, 94%  of 1-15 year population of Virudhunagar District was 
immunized  with  live  attenuated  JE  SA  14-14-2  vaccine  amounting  to  4,83,537 
beneficiaries. 
A total of 178 serum samples were collected from 60 children, selected from 5 
Block PHCs, 12 from each Block PHC, and 3 samples from each child.,  one sample 
prior to vaccination, one sample 4 weeks after vaccination and one sample 12 weeks 
after vaccination.  As one female child from Mallanginar Block PHC refused to give 
post vaccination blood samples, only 178 samples were collected.   
The distribution of samples is given in Table – I.
TABLE – 1
BLOCKWISE DISTRIBUTION OF SAMPLES
Sl.No. Name of Block PHC
No. of children 
selected
No. of Blood 
samples collected
1) Narikudi 12 (20%) 36 (20.22%)
2) Reddiapatti 12 (20%) 36 (20.22%)
3) Pandalkudi 12 (20%) 36 (20.22%)
4) Kanniseriputhur 12 (20%) 36 (20.22%)
5) Mallanginar 12 (20%) 34 (19.10%)
Total 60 (100%) 178 (100%)
It was found that except from Mallanginar Block PHC, equal number of samples 
were collected from all other Block PHCs. 
The distribution of samples were analysed agewise and sexwise and out of 60 
samples collected,  36(60%) were from male children and 24(40%) were from  female 
children .All the samples were from  the age group 6-10 years.
This is given in Table – 2.
TABLE – 2
AGE & SEX WISE DISTRIBUTION OF SAMPLES
Gender
Age in years
0-5 6-10 11-15
Males - 36 (60%) -
Females - 24 (40%)
Total - 60 (100%) -
Thus it was found that all the samples collected were in the age group of 6-10 
years, all school going and more number of samples were collected from males(60%).
All  the  178  blood  samples,  60  pre-vaccinated  and  118  post  vaccinated  were 
screened for IgM antibodies to JE virus with NIV PUNE MAC ELISA KIT.  Among the 
60 pre vaccinated samples, only 2 (3.33%) showed IgM antibodies to JE virus.  Among 
the samples collected after 4 weeks of vaccination, 24 (40.68%) showed sero conversion 
to JE and among the samples collected after 12 weeks of vaccination,   58 (98.30%) 
showed sero conversion to JE virus. 
This is given in Table –3
TABLE –3 
SEROCONVERSION IN PRE &  POST VACCINATION SAMPLES
Block PHC
Pre vaccinated  IgM
(No. of positives/ Total 
No. of samples %)
Samples 
collected 
after 4 weeks 
of 
vaccination 
Samples 
collected 
after 12 
weeks of 
vaccination
1. Narikudi 0 0 12(20.34%)
2. Reddiapatti 0 10(16.95%) 12(20.34%)
3. Pandalkudi               1 (1.66%) 2(3.39%) 12(20.34%)
4. Kanniseriputhur 0 4(6.78%) 11(18.64%)
5. Mallanginar 1 8(13.56%) 11(18.64%)
Total 2/60 (3.33%) 24/59 (40.68%)
58/59 
(98.30%)
It was found that 3.33%  showed IgM antibody to JE virus prior to vaccination., 
40.68%  showed  seroconversion  after  4  weeks  of  vaccination  and  98.3%  showed 
seroconversion after 12 weeks of vaccination. 
The IgM positive samples were analysed sexwise, in the prevaccinated, 4 weeks 
and 12 weeks after vaccination samples  in the 5 Block PHCs and it was noted that in 
pre vaccinated, a male child (12.5%) from Pandalkudi PHC and  a female child (12.5%) 
from Mallanginaru PHC showed sero conversion.    In the samples collected after 4 
weeks  of   vaccination    4  males    each  from  Reddiapatti   PHC  (100%)  and 
Kanniseriputhur  PHC  (40%),   2   males  each  from  Pandalkudi  PHC  (25%)  and 
Mallanginar PHC (50%) showed sero conversion and 6 females each from Reddiapatty 
PHC (75%)  and Mallanginar PHC (85.71%)  showed sero conversion. 
This is given in Tables 4 & 5
TABLE – 4
  IgM  ANTIBODY PROFILE-   PRE VACCINATION SAMPLES 
Place
Number 
of 
samples 
tested
IgM Positives
Male Female
Total 
No. 
collected
Sero 
converted %
Total 
No. 
collected
Sero 
converte
d
%
Narikudi 12 10 - - 2 - -
Reddiapatti 12 4 - - 8 - -
Pandalkudi 12 8 1 12.5 4 - -
Kanniseri
puthur
12 10 - - 2 - -
Mallanginaru 12 4 - - 8 1 12.5
TABLE – 5
IgM ANTIBODY PROFILE-  4 WEEKS  POST VACCINATION.
Place Number 
of 
samples 
tested
IgM Positives
Male Female
Total 
No. 
collected
Sero
converted
%
Total 
No. 
collected
Sero
converted
%
Narikudi 12 10 0 0 2 0 0
Reddiapatti 12 4 4 100 8 6 75
Pandalkudi 12 8 2 25 4 0 0
K.S.Puthur 12 10 4 40 2 0 0
Mallanginar 11 4 2 50 7 6 75
It  was  found  that  there  was  seroconversion  in  both  sexes  equally in  the 
prevaccinated samples suggesting the presence of subclinical cases in both sexes in the 
vaccinated area.  In samples collected after 4 weeks of   vaccination, more male children 
seroconverted in  Pandalkudi, Kanniseriputhur  whereas more females  seroconverted  in 
Reddiapatty & Mallanginar.  No seroconversion was seen in Narikudi in either sex. 
Similarly in the  samples collected after 12 weeks of vaccination, among the 
seroconverted  35(97.22%) were males and 23 were (100%) females.   In these samples 
10 males (100%) from Narikudi, 4 males (100%) from Reddiapatti,  8 males (100%) 
from  Pandalkudi,   9  males  (90%)  from  Kanniseriputhur,  4  males  (100%)  from 
Mallanginar showed seroconversion and 2 females (100%) from Narikudi,  8 females 
(100%) from Reddiapatti, 4 females (100%) from Pandalkudi,  2 females (100%) from 
Kanniseriputhur,  7 females (100%) from Mallanginar showed seroconversion. 
This is given in Table 6
TABLE – 6
IgM ANTIBODY PROFILE- 12 WEEKS POST VACCINATION 
Place Number 
of 
samples 
tested
IgM Positives
Male Female
Total 
No. 
Sero
converted
% Total 
No. 
Sero
converted
%
collected collected
Narikudi 12 10 10 100 2 2 100
Reddiapatti 12 4 4 100 8 8 100
Pandalkudi 12 8 8 100 4 4 100
Kanniseri
puthur
12 10 9 90 2 2 100
Mallanginaru 11 4 4 100 7 7 100
It was found that there was 100% seroconversion in females in all block PHCs 
whereas  in  males  except  Kanniseriputhur,  all  other  block  PHCs  showed  100% 
seroconversion. 
The antibody titre of all the 178 samples were also determined by HI technique. 
In the prevaccinated IgM positive samples, one male child  from Pandalkudi PHC,  one 
female from Mallanginar PHC , showed HI titre of 1 in 160 confirming the  presence of 
subclinical case prevalence in these two Blocks.  
This is given in Table – 7
TABLE – 7
HI TITRE  PROFILE -PRE VACCINATION SAMPLES.
Place
Number of 
samples 
tested
IgM Positives
Male Female
Total 
No. 
collected
Sero
converted
%
Total 
No. 
collected
Sero
converted
%
Narikudi 12 10 - - 2 - -
Reddiapatti 12 4 - - 8 - -
Pandalkudi 12 8 1 12.5 4 - -
Kanniseri
puthur
12 10 - - 2 - -
Mallanginaru 12 4 - - 8 1 12.5
                 
In the samples collected after 4 weeks of vaccination,   out of 59 vaccinated, 24 
showed  HI titre (40.68%).  In Narikudi, out of 12 vaccinated , no cases was  shown with 
antibody titre,  in Reddiapatty  4 showed antibody titre 1 in 160, 6 showed 1 in 320 and 
two sample were negative. In Pandalgudi, 2 samples showed antibody titre 1 in640.  In 
Kanniseriputhur, 2 showed 1 in 160,  2 showed 1 in 320, In Mallanginar, out of 11, 2 
showed 1 in 80, 5 showed 1 in 320,  1 showed 1 in 2560. 
This is given in Table 8
TABLE – 8
LOCALE & SEX WISE DISTRIBUTION OF HI TITRE OF  4 WEEKS POST  VACCINATION SAMPLES.
Area
N
o.
 o
f s
am
pl
es
 
Te
st
ed
HI TITRE
Nil 1 : 20 1 : 40 1 : 80 1:160 1:320 1:640 1:1280 1:2560 Total
M F M F M F M F M F M F M F M F M F M F
Narikudi 12 - - - - - - - - - - - - - - - - - - - -
Reddiapatti 12 - - - - - - - - -
4
50%
4
100%
2
25%
- - - - - -
4
100%
6
75%
Pandalgudi 12 - - - - - - - - - - -
2
25%
- - - - -
2
25%
-
K.S.puthur 12 - - - - - - - -
2
20%
-
2
20%
- - - - - - -
4
40%
-
Mallangina
r 11 - - - - - - -
2
28.6%
- -
2
50%
3
42.9%
- - - - -
1
12.3%
2
50%
6
85.7%
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Thus among the seroconverts, 2 females (8.7%) showed 1 in 80, 2 
males  (5.56%)  and  4  females  (17.4%)  showed  1  in  160,  and  8  males 
(22.2%) and 5 females (21.7%) showed 1 in 320, 2 males  (8.7%) showed 
1in  640,and  1  female  (4.35%)  showed  1  in  2560  after  4  weeks  of 
vaccination.   After  4  weeks  of  vaccination,    both  males  and  females 
showed HI titres and 1 in 2560 titre was seen in 1 female. 
       In the samples collected after 12 weeks of vaccination, out of 59 
vaccinated, 1 male (2.78%) from Kanniseriputhur showed no HI titre, and 
58 showed HI titre(98.30%).  Out of the 58 HI titre positives samples,  5 
males  (13.89%)  showed  1  in  20,  10  males  (27.78%)  and  6  females 
(26.08%) showed 1 in  40,  6  males (16.67%) and 6 females   (26.08%) 
showed 1 in 80,  8 males (22.22%) and 2 females (8.7%) showed 1 in 160, 
4  males  (11.11%) and 3 females  (13.04%)  showed 1  in  320,  2  males 
(5.56%) and 6 females (26.08%) showed 1 in 640.  
Further HI titre analysis of the samples collected after 12 weeks of 
vaccination, showed that in  Narikudi  Block PHC all the samples who 
had no antibody titre in the sample collected after  4 weeks of vaccination, 
showed titre in the range of 1 in 20 to 1 in 320.   In Reddiapatti Block 
PHC   4  females   showed four  fold  increase  in  HI  titre  in  the  sample 
collected  after  12  weeks  of  vaccination,  .  2  females   showed  2  fold 
increase in titre,  2 males showed no increase in titre,   2 females showed 1 
in 320 titre, only in the sample collected after 12 weeks of vaccination,  2 
males showed decrease in titre,
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In Pandalgudi Block PHC  2 females and 4 males showed 1 in 80 
titre  only in the sample collected after 12 weeks of vaccination,  2 females 
showed 1 in 40 in the sample collected after 12 weeks of vaccination, 1 
male  showed  1  in  160  in  prevaccinated,  1  in  640  titre  in  the  sample 
collected after 4  weeks and 12 weeks of vaccination, 2 males showed 1 in 
160 only in the sample collected after 12 weeks of vaccination,  1 male 
showed two fold increase in titre. 
In Kanniseriputhur Block PHC  3 males showed 1 in 20, only in 
the sample collected after 12 weeks of vaccination, 2 males showed 1 in 
80, only in the sample collected after 12 weeks of vaccination,  2 males 
showed four fold  decrease in titre,   2 females showed 1 in 40, only in the 
sample collected after 12 weeks of vaccination,    2 males showed 2 fold 
decrease in titre,   1 male who had  no titre in  pre vaccinated, and the 
sample collected after 4 weeks of vaccination also showed no titre in the 
sample collected after 12 weeks of vaccination. 
In Mallanginar Block PHC  3 females showed four fold  decrease 
in titre, 2 males showed two fold  decrease in titre, 2 females showed a 
titre 1 in 40, only in the sample collected after 12 weeks of vaccination,  1 
female who had 1 in 160 in prevaccinated sample, 1 in 2560 in the sample 
collected after 4 weeks of vaccination, showed a decrease in titre 1 in 160, 
2 females showed two fold decrease in titre,  2 females showed 1 in 160 
only in the sample collected after 12 weeks of vaccination. 
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This is given in Table-9
TABLE – 9
LOCALE & SEX WISE DISTRIBUTION OF HI TITRE  12 WEEKS AFTER VACCINATION  
Area
N
o.
 o
f s
am
pl
es
 T
es
te
d HI TITRE
Nil 1 : 20 1 : 40 1 : 80 1:160 1:320 1:640 1:1280
1:256
0 Total positives
M F M F M F M F M F M F M F M F M F M F
Narikudi 12 - -
2
20%
-
4
40%
- -
2
100%
2
20%
-
2
20%
- - - - - - -
10
100%
2
100% 
Reddiapatti 12 - - - -
2
50%
- - - - -
2
50%
2
25%
-
6
75%
- - - -
4
100%
8
100%
Pandalgudi 12 - - - - -
2
50%
4
50%
2
50%
2
25%
- - -
2
25%
- - - - -
8
100%
4
100%
K.S.puthur 12
1
10
%
-
3
30%
-
2
20%
2
50%
2
20%
-
2
20%
- - - - - - - - -
9
90%
2
100%
Mallanginar 11 - - - -
2
50%
2
28.6%
-
2
28.6%
2
50%
2
28.6
%
-
1
14.3
%
- - - - - -
4
100%
7
100%
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Among the 24 samples, who had HI titre in the sample collected 
after 4 weeks of  vaccination,  14 showed a decrease in titre  in the 
sample collected after 12 weeks of vaccination 7 showed a increase in 
titre, 3 showed no change in titre after 12 weeks of vaccination.   34 
childrens who had no HI titre in the sample collected after 4 weeks of 
vaccination also showed HI titre in the range of 1 in 20   to  1 in 640.  
A male from Kanniseriputhur showed no titre in all 3 samples. Thus 
there  is  evidence  that  antibody  titre  increased  in  all  the  samples 
except one from Kanniseriputhur. 
The  samples  which  showed  antibody  titre  by  HI  were  further 
confirmed with Mouse Neutralisation Test.  Out of 59 samples inoculated 
in mice all the samples except the one from Kanniseriputhur showed 
Neutralizing antibodies, thus confirming the presence of JE antibody 
in these samples.   The mice survival ratio was less than 30% in the 
sample from Kanniseriputhur. 
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This is given in Table 10
TABLE – 10
NEUTRALIZING ANTIOBODIES VS   MNT OF THE SAMPLES 
COLLECTED AFTER 12 WEEKS OF VACCINATION 
Area
No. of 
Sample 
Tested
Mice Survival ratio 
70-100% 31-69% < 30%
Narikudi 12 12 + - -
Reddiapatti 12 12 + - -
Pandalgudi 12 12 + - -
Kanniseripudur 12 11 + - 1+
Mallanginar 11 11 + - -
Total 59 58 + - 1+
Thus the efficacy of the vaccine was proved by the seroconversion 
in the samples collected in all 5 Block PHCs at Virudhunagar by both HI 
and MNT. 
The  efficacy  of  the  vaccine  was  further  confirmed  by  the  case 
study also.  The number of cases & deaths reported in the year 2006-07 
before vaccination were compared with the number of  cases & deaths in 
the year 2007-08 and it was found that there were 3 cases and 1 death 
from September 2006 to August 2007 in the age group of 1-15 years at 
Virudhunagar District,. whereas there was no case and no deaths reported 
from  September  2007  to  August  2008  in  Virudhunagar  District  after 
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vaccination showing that this vaccine has protected the population of 1-
15  years  in  this  district  with  marked  rise  in  antibody  titre  in  the 
vaccinated individuals. 
This is given in Table 11
TABLE – 11
YEAR WISE COMPARISON OF CASE FATALITY RATE 
From September 2006  to 
August 2007
From September 2007  to 
August 2008
No. of samples 
with Acute 
encephalitis 
manifestations
No. of 
positives 
%
No. of samples 
with Acute 
encephalitis 
manifestations
No. of 
positives 
%
Cases 6 3(50%) 9 -
Deaths 6 1 (16.67%) 9 -
Further  evaluation of  safety  of  this  JE SA 14-14-2 vaccine was 
analysed by noting the local reaction and systemic toxicity if any, which 
occured after the vaccination and it was shown that swelling was present 
in 1 child (1.67%) in Narikudi, headache was present in 1 child (1.67%) 
in  Pandalgudi.   No cases  of  encephalitis  /  meningitis,  seizure  were 
detected in any Block. 
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This is given in Table 12
TABLE – 12
REPORTED SIDE EFFECTS OF LIVE ATTENUATED JE SA 14-
14-2 VACCINE
Area No. of children
Local 
reaction
Systemic 
toxicity Encephalitis
Narikudi 12 *1 (1.67%) - -
Reddiapatti 12 - - -
Pandalgudi 12 - **1 (1.67%) -
Kanniseripudur 12 - - -
Mallanginar 12 - - -
Total 60 1 (1.67%) 1 (1.67%) -
* Swelling present.
** Headache present.
Thus it was proved to be safe for the age group 6-10 years in all the 
block PHCs at Virudhunagar in all the vaccinated children.
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DISCUSSION
The study on Efficacy and Safety of SA 14-14-2  vaccine against 
Japanese Encephalitis virus at Virudhunagar District was conducted 
in 5 Block areas from October 2007 to December 2007.  
As the population selected in the study was only the school going 
children, the age group involved in the study was from 6-10 years. 
Similar  study by  C.V.R. Mohan Rao et al 1992 also involved school 
going  children  of  this  age  group  for  the  study  of  efficacy  of   JE 
vaccination at South Arcot District in 1992.  As the ratio of school going 
males exceeded females in this District, the sample collection  was also 
more in the males in this study. 
In  this  study,  it  was  shown that  3.33% subclinical  cases  were 
present in the population with IgM antibody in prevaccinated samples. 
Similar findings were also found in the study by C.V.R. Mohan Rao et al 
which showed 42.48% subclinical cases in South Arcot District.  In Tamil 
Nadu,  Virudhunagar  District,  Vilupuram,  Thiruvarur,  Thanjavur  and 
Perambalur Districts have already proved to have JE cases and deaths 
reported from 1991.  Similar study by  A.Gajanana et al 1989 showed 
that in the non transmission season there may be considerable decline in 
seropositivity  of  general  population.  The  samples  in  this  study  were 
collected before the transmission season and this may be the reason for 
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the decline in the number of subclinical cases. 
In this  study,  it  was found that  40.68% sero converted after 4 
weeks  of  vaccination and  98.3%  seroconverted  after  12  weeks  of 
vaccination. A similar study by Young Mo Sohn et al 1998  showed that 
16%  seroconversion  was  seen  in  their   vaccinees   after  4  weeks  of 
vaccination.  Indian Paediatrics 2001 reported that IgM antibodies after 
JE infection arises by 3rd day of onset and maximum at 7th day and last 
upto 3 months, but the studies on immunization by Theodar et al showed 
that  94  –  100% seroconversion can  be  expected  only  after  2  primary 
doses of SA 14-14-2 vaccine at intervals of 1 month and  2.5 month.  In 
this study also eventhough only one dose was given, the seroconversion 
was 98.3% after 12 weeks.  Thus there is variation in seroconversion after 
viral infection and immunisation.   The viral vaccines are prepared by 
serial cell culture passages and neuro attenuation, hence the nucleotide 
sequence of  the vaccine gets  varied.   So the immune response  in  the 
disease may not be similar to that after vaccination. 
In this study, it was found that Narikudi Block PHC was the only 
one where there was no seroconversion after 4 weeks.  The article by 
Theodar F Tsai  showed that lower seroconversion rates were mainly due 
to the vaccine dilutions.  In this vaccine, the expected infectious titre, for 
the minimal standard of vaccine infectivity should not be less than 106.7 
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TCID50 per  ml.   As  Narikudi  is  the  only  block  which  showed  no 
seroconversion  after  4  weeks,  it  is  obvious  that  there  might  be  some 
technical deficiencies in vaccine dilutions.  
After  12  weeks,  it  was  noted  that  7  children  showed  marked 
increase in titre, whereas 14 showed decrease in titre and 3 showed no 
change  in  titre.   It  was  already  shown  in  studies  in  Asia  that  the 
persistence  of  vaccine-derived  immunity  are  complicated  by  natural 
infections  with  dengue,  West  Nile  virus,  or  other  flaviviruses  and 
reexposure to JE virus itself, all of which act to reinforce and broaden 
vaccine-derived immunity to JE virus.101,102,122-124,153.   Perhaps this might 
have occured in this population also because this area is also endemic for 
Dengue  and Westnile and other flavi viruses. 
In this study it was shown that  one child had no seroconversion 
at all.  It is already shown by Mohammed Zeeshan et al that failure of 
immune  response  in  their  vaccination  studies  was  due  to  nutritional 
status,  site  of  administration  of  vaccine  and  genetic  factors.    These 
factors  might  be  the  reason  for  no  immune  response  in  one  child  in 
Kanniseriputhur.   
In this study, seroconversion was  diagnosed by identifying both 
HI antibodies and Neutralizing antibodies.  Thus these 2 tests were 
used  to  study  the  efficacy  of  the  vaccine.   This  demonstration  of  HI 
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antibodies for seroconversion was already done by C.V.R. Mohan Rao et 
al  and also proved by  Gajanana et al  that HI has several advantages 
making it  particularly  appropriate  for  subclinical  infections  as  well  as 
post infection phase.  It is a sensitive accurate indicator needing only a 
small quantity of serum or plasma and also HI antibodies develop faster 
than the neutralizing antibodies and previously infected person may show 
measurable antibody responses.  In this study also HI technique detected 
subclinical  cases and post  vaccinated cases in different  periods that  is 
after 4 weeks and 12 weeks. 
The  serum antibody  determination  by  mouse  neutralization  test 
after JE vaccine was detected by C.V.R. Mohan Rao et al in a study at 
South Arcot District and proved mouse survival ratio between 70-100% 
as positive and below 30 as negative.  In this study it was shown that 
there was only one sample which showed survival rate below 30% giving 
negative  neutralization  test.   Thus  in  this  study,  there  was  only  one 
sample which was negative for both HI  and neutralizing antibodies.  All 
the other samples showed HI titres varying from 1 in 80  to 1 in 2560 and 
mice survival rate between 70-100%. Thus the study of seroconversion 
by 2 methodologies  confirm the presence of  serum antibodies for  JE 
virus. 
In  this  study,  the  efficacy  of  the  vaccine  was proved  by 
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comparing the fatality rate of AES cases in 2007 prior to vaccination and 
in  2008  ,  after  vaccination.  It   was   found  that  prior  to  vaccination, 
Virudhunagar reported 3 JE positive cases and  one death due to JE in 
2007 and there were no JE positive cases and deaths due to JE in 2008. 
Thus JE vaccine is proved to be  highly efficient in preventing JE virus. 
A similar study by  Bista M.R. et al also showed that JE vaccine was 
highly efficient in preventing JE when administered before exposure to 
virus. His study with 20 children confirmed the present study.  Similar 
study by Konishi E  et al 2002  also showed and evaluated the protective 
capacity of the approved inactivated JE vaccine by comparing the ratio 
with those reported for unvaccinated population. 
The safety of the vaccination was evaluated by observing the 
local reaction and systemic toxicity .  It was shown that except for one 
case with swelling, and one with mild headache no other symptoms were 
observed, proving the safety of the vaccine.  Similar study by  Ma F B, 
Zeng L et al  revealed that 1.6% local reaction alone was seen in the 
vaccinees and the vaccine was proved to be effective and safe.  Similarly 
KuZuhara S et al 2003 also demonstrated that the advanced reactions, 
headache and malaise  were mild occuring at a rate of 6.7% proving that 
this vaccine was safe and effective. 
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SUMMARY
“The  study  on  Efficacy  and  Safety  of  SA-14-14-2  vaccine 
against  Japanese  Encephalitis  Virus  at  Virudhunagar  District” 
revealed the following. 
• There were sublclinical cases in the area selected for the vaccine study 
which  was  demonstrated  by  the  presence  of  IgM antibodies  to  JE 
virus. 
• After  4  weeks  of  vaccination,  40.68%  vaccinated  children 
seroconverted  and  after  12  weeks  of  vaccination  98.3% 
seroconverted. 
• The efficacy of the vaccine was proved by the seroconversion in both 
males  and  females  equally  and increase  in  titre  in  all  the  samples 
except one at Kanniseriputhur.  This child was a malnourished child. 
• In Narikudi Block PHC there was slow seroconversion probably due 
to improper vaccine dilutions.  
• The two confirmatory tests used for the seroconversion, were  HI test 
and MNT.    The efficacy  of  the vaccine  was also  proved by case 
study. There was no JE case / deaths after the vaccination in the study 
area. 
• The  safety  of  the  vaccine  was  evaluated  by  observing  systemic 
toxicity and  local reaction   which proved to be of negligence rate in 
the  vaccinated  children,  hence  the  safety  of  the  vaccine  was 
confirmed. 
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CONCLUSION
The  study  on  “Efficacy  and  Safety  of  SA 14-14-2  vaccine 
against  Japanese  Encephalitis  Virus  at  Virudhunagar  District” 
showed 
• There   was  subclinical  cases  (3.33%)   in  the  study  population  at 
Virudhunagar District. 
• 98.3% samples showed seroconversion after 12 weeks of vaccination 
equally in both sexes. 
• Only  one  sample  from  a  malnourished  child  at  Kanniseriputhur 
showed no seroconversion. 
• Narikudi Block PHC showed slow seroconversion. 
• The  eifficacy  of  the  vaccine  SA-14-14-2  was  confirmed  by  the 
seroconversion methods. (HI & MNT) and also case  study. 
• The absence of systemic toxicity & local reactions proved the safety 
of the vaccine.   
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ANNEXURE - I
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ANNEXURE - II
ANNEXURE - III
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PREPARATION OF REAGENTS
I. Borate Saline pH 9.0
1.5M NaCl - 160 ml
0.5M H3BO3 - 200 ml
1N NaOH - 47 ml
Add double D.W. to make 2 litre, pH 9.0 (if pH is not 9.0 then add 
0.5M H3BO3or IN NaOH to adjust)
 
II. 0.4% percent Bovine Albumin in Borate Saline (BABS) pH 9.0
Bovine Albumin - 4.0 gm
Borate Saline pH 9 - 100 ml
Keep overnight in cold and adjust pH to 9.0 with 1M NaOH. Take 
100 ml of this solution and add to 900 ml of borate saline solution, pH 
9.0.
III. 25% Percent Kaolin in Borate Saline pH 9.0
Kaolin (acid washed) - 25 gm
Borate Saline pH 9.0 - 100 ml
Stir  Borate  Saline  on  magnetic  stirrer  and  add  Kaolin  powder 
slowly till uniform suspension is obtained.
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IV. 0.9% % NaCl
NaCl - 9 gm
Double distilled water (DDW) - 1000 ml
Autoclave at 15 Ibs for 15 minutes. 
V. Acid Citrate Dextrose (ACD)
Sodium Citrate - 11.26 gm
Citric Acid - 4.0 gm
Dextrose - 11.0 gm
DDW - 500 ml
Autoclave at 15 Ibs for 10 minutes.
VI. Dextrose Gelatin Veronal
A. Veronal (Diethyl barbituric acid) - 0.580 gm
      Gelatin - 0.600 gm
                Hot D.D.W. -    250 ml
B. Sodium Barbitone - 0.380 gm
     MgSO47H2O - 0.120 gm
               CaCl2 (anhydrous) - 0.020 gm
     NaCl -  8.5 gm
               Dextrose - 10.0 gm
               Merthiolote - 0.1 gm
     D.D.W - 750 ml
Mix A and B solutions.  Autoclave at 10 Ibs for 10 minutes.
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VII. METHOD FOR PREPARATION OF PHOSPHATE BUFFER 
        SALINE(PBS).
I. PBS(10x)
Nacl                     - 80.0 gms
Kcl                       - 2.0 gms
Na2H PO4           - 11.5 gms
KH2PO4              - 2.0  gms
H2O to make - 1000 ml.
Store at 40c
II  Mgcl2.6H2O (100x)
Mgcl2.6H2O - 1.0 gms .
H2O - 100 ml
Autoclave at 15 Ibs for 15 minutes .Store at 40c
III Cacl2.2H2O(100x)
Cacl2.2H2O - 1.8 gms .
H2O - 100.0 ml .
PBS(Dilute) for actual use
A        PBS(10x)                                            - 100.0 ml
           H2O                                                   - 880.0 ml
       Autoclave at 15 Ibs for 15 minutes.Wait until cool and then add (b) 
and (c) as mentioned below.
(b)   Mgcl2.6H2O(100x)       II - 10.0 ml.
(C)   Cacl2.2H2O(100x)        III - 10.0  ml .
Store at 50c.
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